ENHANCING PROVIDER PERFORMANCE & CLINICAL INTEGRATION Q4 2020 | V 15 NO. 4 | HEALTHTRUST
HealthTrust’s 2020 Member Recognition Award Recipients BEST OF THE BEST | pages 42 – 45
CARING CLOSE TO HOME HealthTrust members prioritize patients with innovative solutions
SUSTAINING POSITIVE CHANGE Key initiatives from the most sustainable hospitals
BEAUMONT HEALTH RECEIVES HEALTHTRUST’S 2020 OUTSTANDING MEMBER AWARD
Q4 2020 | V 15 NO. 4 | HEALTHTRUST FEATURES
38 CARING CLOSE TO HOME Member facilities prioritize the health & safety of their patients & communities during the pandemic with innovative solutions.
EDITORIAL CONTRIBUTIONS: Clinicians and staff within HealthTrust member facilities are invited to share their expertise as part of upcoming stories. Readers are also invited to suggest other experts for interviews or article ideas for publication consideration. Preference is given to topics that represent: * Clinical or supply chain initiatives that exemplify industry best practices * Physician Advisor expertise * Innovation, new technology, insights from data and analytics 42 * Positive impacts to cost, quality, outcomes and/or the patient experience BEST OF THE BEST Contact Faye Porter at faye.porter@ HealthTrust 2020 Member Recognition Award recipients stand out for their healthtrustpg.com with suggestions. (Note: HealthTrust reserves the right commitment to excellence. to edit all articles and information accepted for publication.) HealthTrust (Healthtrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence Member address changes: Contact through an aligned membership model and the delivery of total spend management advisory solutions that leverage our [email protected] operator experience, scale and innovation. Headquartered in Nashville, Tennessee, HealthTrust (healthtrustpg.com) serves Advertising, reprints or permissions: over 1,600 hospitals and health systems, and more than 55,000 other member locations including ambulatory surgery Contact [email protected] centers, physician practices, long-term care and alternate care sites. Follow us on Twitter @healthtrustpg. Mail: The Source, c/o HealthTrust, 1100 Dr. Martin L. King Jr. Boulevard, Content ©2020 by HealthTrust. All rights reserved. No part of this publication may be reproduced, in any form, without prior Suite 1100, Nashville, TN 37203 written permission from HealthTrust. HLT-014
Fourth Quarter 2020 | 1
DEPARTMENTS 2020 EDUCATION & EDITORIAL ADVISORY BOARD STARTING LINE PUBLISHER Michael Schlosser, M.D., FAANS, MBA – CMO, Ed Jones HCA National Group & VP, Clinical Excellence & 04 CEO perspective President/CEO Surgical Services 06 CMO perspective Kent Petty, CHCIO – Chief Information Officer, HealthTrust EXECUTIVE PUBLISHER & Jocelyn Bradshaw – SVP, Strategic Sourcing EDITOR-AT-LARGE David Osborn, Ph.D. – SVP, Strategic Accounts & John Young, M.D., MBA, CPE, FACHE Advisory Services VITAL SIGNS Chief Medical Officer Shelly Workman – SVP, Supply Chain 09 Product vigilance for hand Allen Wright, MBA – SVP, Strategic Sourcing, sanitizers & masks EXECUTIVE PUBLISHERS Commercial Products & Services Crystal Dugger, MBA, RN Teri Bernstein – VP, Strategic Sourcing 12 In search of an alternative to VP, Clinical Services Barbara Carlston, MBA – VP, Member Services imported drugs Angie Mitchell, RN Cathy Florek – VP, Supply Chain Board/GPO Operations AVP, Clinical Services Vincent Jackson, PharmD – VP, Pharmacy Services Bob Davis – AVP, Marketing & Communications OPERATOR EXPERIENCE EXECUTIVE EDITOR Joey Dickson – Chief Diversity Officer & AVP, Faye Porter Purchased Services & Diversity Contracting 14 Making it work: Innovations in Director, Member Education & Jennel Lengle, MSN, RN – AVP, Clinical Operations staffing during COVID-19 Communications, Clinical Services Kimberly Wright, RN – AVP, Clinical Data Solutions, Clinical Services CONTRIBUTING EDITOR Jason Braithwaite, PharmD, MS, BCPS – Senior Director, Shellie Meeks Pharmacy Services CONSIDER THIS Manager, Member Education & Margherita Potter, MHS, RD, BS – Senior Director, 20 The doctor will see you now: Communications, Clinical Services Food & Nutrition Services Virtual waiting rooms enhance Karen Bush, MSN, FNP, BC, NCRP – Director, Clinical EDITORIAL & CREATIVE SERVICES Research & Education, Clinical Services telehealth services Cara Finnegan Tara Coleman, MBA, BSN, RN – Director, Nursing 26 Breathing life into new Editor, GLC Services, Clinical Operations Luann Culbreth, MEd, MBA, RT, FACHE – Director, technology with the X-VENT Paula Rosenberg Frey, BSN, MS Radiology & Cardiovascular Services, Clinical Operations ventilator Contributing Editor, GLC Kim Kelly, MSN, RN – Director, Clinical Categorization & HealthTrust Advisor App 32 Mercy Health System creates Enrique “Rick” Cruz Sarah Michel, MBA, BSN, RN, NE-BC – Director, algorithm to conserve PPE Art Director, GLC Research & Clinical Engagement, Clinical Services Holly Moore, MSN, CCRN-K – Clinical Director, Clinical 36 Trending Data: The impact of Services COVID-19 THE SOURCE (ISSN 1932-7862) is published Christa Pardue, MBA, MT(AMT) – Director, Laboratory by HealthTrust, 1100 Dr. Martin L. King Jr. Services, Clinical Operations Boulevard, Suite 1100, Nashville, TN 37203 Kym Smith, RN – Clinical Director, Clinical Services BY EXAMPLE Jennifer Westendorf, MSN, RN, CNOR – Director, POSTMASTER: Send address changes to Surgical Services, Clinical Operations 46 Sustaining positive change HealthTrust at the address listed above or 50 HealthTrust’s commitment to by emailing: [email protected] diversity contracting Note: The articles and information that appear in the print or online versions of The Source are for informational purposes IN THE KNOW only and should not be relied upon in any 56 Decoding the language of caring manner. Individuals should independently 26 determine, and shall have sole responsi- with the universal Clinical Care bility for, any course of action related to Classification System, SabaCare the matters addressed herein. HealthTrust expressly disclaims any liability associated 60 Scam alert: What you need to with actions or omissions of any individual know about antibody test claims relying upon such content. Contact [email protected] for additional information.
HTU Call for Proposals ... Submit ideas by Dec. 16 at conferenceabstracts.com/ healthtrust2021.htm. See page 16 50 for details
2 | Fourth Quarter 2020 Collaborative imaging Made possible.
Working together to understand your needs and challenges drives valuable outcomes that positively impact you and your patients’ future. HealthTrust Canon Medical’s vision and commitment to improving life for all, lies at the heart of Contract Number everything we do. By partnering to focus on what matters, together we can deliver intelligent, high quality solutions. #500348 With Canon Medical, true innovation is made possible.
CANON MEDICAL SYSTEMS USA, INC. us.medical.canon ©Canon Medical Systems, USA 2019. All rights reserved. Design and specifications subject to change without notice. STARTING LINE CEO perspective Explore purchased services for additional cost savings
As providers across the country Valify Solutions Group is led by Chris manage the pandemic-inspired Heckler as CEO, and the consulting arm new normal, initiatives to make up for is led by Andy Motz as AVP of Consulting. lost revenue opportunities are paramount to There is no cost to join the purchased help drive financial resiliency. An area often services GPO, and hospitals can selectively overlooked for substantial cost savings is choose from 260+ contracts, representing purchased services. more than $8 billion in spend. VSG Annual purchased services spend for combines Valify’s market-leading U.S. hospitals is estimated at more than technology with HealthTrust’s best-in-class $300 billion—comprising up to 45% of contract portfolio and advisory services a hospital’s nonlabor operating expense. to create the industry’s first end-to-end It’s an area often difficult to manage due purchased services program, inclusive of to the complexity of unique categories, sourcing, spend analytics, benchmarking, decentralized decision-making and contract management, negotiations, contract management, and a lack of advisory services and custom contracting. operational metrics. We are excited to share this opportunity Over the last decade, HealthTrust has with you. built a robust portfolio of more than 260 Continued on page 8 purchased services contracts, spanning a wide range of health system functions— from landscaping and building maintenance to intraoperative neuromonitoring and parking/valet services. In more recent years, as part of our inSight Advisory Solutions, we established consulting services to help move members toward a path of cost savings. On average, this team saves our members 10% to 25% in the categories for which they provide consulting services. To expand our offerings in this area, I’m excited to announce that over the summer, we launched Valify Solutions Group (VSG)— the first tech-enabled purchased services group purchasing organization (GPO) for healthcare. This new GPO leverages the largest data-driven market intelligence platform of more than $460 billion in total spend, categorized through proprietary Ed Jones machine-learning algorithms to generate President/CEO, HealthTrust benchmarking insights for its members. Publisher, The Source magazine
4 | Fourth Quarter 2020 This way forward. A lot has changed over the last year, but one thing has always stayed the same—our commitment to helping you provide the best possible care and continue to improve patient outcomes. We strive to help protect your caregivers and patients with solutions for surgical operations, outpatient care, infection prevention and respiratory protection. We’re proud to partner with you to deliver high-quality care in today’s world by helping you to: • Ge t back to business • H elp to reduce the risk of surgical site and healthcare associated infections • E mpower your post-op process
HealthTrust Contracts #576, 735, 746, 931, 6901, 38570
Find your way forward at 3M.com/Medical.
©2020 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. PRA-PM-US-02709 (09/20) STARTING LINE CMO perspective New realities, courtesy of the pandemic
HealthTrust University Conference, online due to the pandemic. While it was certainly not the event classes, society and industry meetings, even patient any of us anticipated when we began planning for 2020, our visits—are you becoming acclimated to the virtual presenters’ adaptability to the format enabled us to deliver a experience? Most of us have found ways to adapt. Although quality slate of education to the HealthTrust membership. some aspects of medicine don’t translate perfectly in a Special thanks to Physician Advisor Jeffrey Hodrick, M.D.; virtual model, it’s proven to be an effective way to treat some CMOs Christopher Ott, M.D. (HCA Healthcare Physician patients during the pandemic. Services Group) and Christopher Rehm, M.D., (LifePoint As the article on page 20 reveals, 46% of Americans Health); and VP of Quality David Stepansky, M.D. (CHS), for have elected to use telemedicine in light of safety concerns. their participation in two of the HTU online sessions. Visit Through initiatives to improve telemedicine efficiencies, a the public education site (healthtrustpg.com/education) or new concept has emerged—virtual waiting rooms. Physician the education section of the Member Portal for access to a Advisors William Payne, M.D. (Franciscan Alliance), and number of the HTU sessions. Kevin Yoo, M.D. (California Cancer Associates for Research & Excellence), share how they use this technology to reduce wait times.
THE BENEFITS OF VIGILANCE As part of its normal course of business, HealthTrust vets products that may be added to its contract portfolio. Clinical Advisory Boards support sourcing by applying evidence and knowledge to the process. As HealthTrust’s Karen Wagener, BS, ChE; Carey Watkins, RN, MSN; and Angie Mitchell, RN, explain in the article on page 9, this vetting process has proved itself invaluable during the pandemic in protecting members against subpar products and bait-and- switch tactics from unscrupulous suppliers intending to take advantage of providers impacted by the personal protective equipment (PPE) shortage. HealthTrust’s decisions also typically align with Food and Drug Administration (FDA) guidance and product approvals. But the pandemic compelled the FDA to ramp up product reviews, and the agency has recognized many unproven John Young, M.D., MBA, CPE, FACHE medical products—some with fraudulent claims—over the Chief Medical Officer, HealthTrust last several months. Karen, Carey and Angie share that, while Executive Publisher & Editor-at-large, The Source magazine it was necessary for the FDA to do what it did to ensure hospitals didn’t have even more shortages of PPE, it shifted the burden of legitimacy to the purchaser. JOIN HealthTrust’s recently launched COVID community HEALTHTRUST UNIVERSITY HIGHLIGHTS to access related content, interact with peers and learn best practices. Email [email protected] to join The annual HealthTrust University Conference was offered the discussion. for the first time in a virtual environment in early August
6 | Fourth Quarter 2020 1-MONTH1-MONTH1-MONTH1-MONTH1-MONTH1-MONTH DAPT DAPT DAPT DAPT DAPT EVIDENCEEVIDENCEEVIDENCEEVIDENCEEVIDENCEEVIDENCE ININININ INCOMPLEX INCOMPLEX COMPLEXCOMPLEX COMPLEX COMPLEX PATIENTSPATIENTSPATIENTSPATIENTSPATIENTSPATIENTS OnyxOnyxOnyx ONE ONE ONEMonth Month Month DAPT DAPT DAPT Program Program Program OnyxEvaluatingOnyxEvaluating ONEEvaluatingOnyx ONE Month Resolute ONE MonthResolute Resolute DAPT Month OnyxDAPT OnyxProgram DAPT Onyx™ Program DESDES™ DES Program™ ininDES in in EvaluatingEvaluatingEvaluating Resolute Resolute Resolute Onyx Onyx™ DES Onyx™ DES in™ DES in in ResoluteResoluteResoluteResolute OnyxOnyx Onyx DESDES Onyx DES DES ~1,700~1,700~1,700 patients patients patients withwith with 1-monthwith 1-month 1-month DAPT. DAPT. DAPT. ResoluteResolute OnyxResolute DES Onyx OnyxDES DES ~1,700~1,700 patients~1,700 patients patients with with 1-month with 1-month 1-month DAPT. DAPT. DAPT.
ONYXONYXONYX ONE ONE ONE ONYXONYXONYX ONE ONE ONE ONYXONYXONYX ONE ONE ONE MONTH MONTH MONTH ONYXGLOBALONYXGLOBALGLOBAL ONEONYX ONE STUDY STUDY ONE STUDY ONYXCLEARONYXCLEARCLEAR ONEONYX S TUDYONE STUDY SONETUDY ONYXDAPTDAPTONYXDAPT ONE ONYXPROGRAM PROGRAM ONE MONTH PROGRAM ONE MONTH MONTH GLOBALFirstGLOBALFirst prospective,First prospective,GLOBAL STUDYprospective, STUDY STUDY CLEARFirstFirstCLEAR studyFirst study CLEARS inTUDY study the inS theTUDYU.S. in theSU.S. TUDY U.S. DAPTTheTheDAPT most ThePROGRAM mostDAPT robust most PROGRAM robust robustclinicalPROGRAM clinical clinical Firstrandomized,randomized, prospective,Firstrandomized,randomized, prospective,First 1-month 1-monthprospective, 1-month 1-month DAPTDAPT DAPT DAPT Firstandand studyFirstand JapanJapanand Japan study Firstin evaluatingevaluatingtheJapan study evaluatingin U.S. the evaluating in U.S. the U.S. Theprogram mostprogramTheprogram mostrobust Thestudying studying most robust clinical studying 2,700 robust clinical2,700 2,700 clinical randomized,trialtrialrandomized,trial comparingcomparingtrial comparingrandomized, 1-monthcomparing a a1-month DESDES a DESDAPT 1-monthto toa DES aa to DAPT a to DAPTa and1-month Japanand1-month1-month Japan andevaluating DAPT JapanDAPT evaluating duration DAPT evaluatingduration duration programhighlyhighlyprogram complex highlystudyingprogram complex studyingcomplex HBR 2,700 studying HBR patients 2,700 HBR patients 2,700 patients trialDES in comparingtrialDES in highDES incomparingtrial high bleeding comparing ahigh DESbleeding ableeding toDES risk a a risk to DES arisk to a 1-monthinin HBRHBR1-monthin HBR inpatients with patients withDAPT1-month HBR patients with DAPT patients withduration DAPT duration duration highlywithwithhighly complex1-monthwith 1-monthhighly complex 1-month HBR DAPT. complex DAPT. patients HBR DAPT. HBRpatients patients DES in(HBR) patients.(HBR) patients.DES in(HBR) patients. high(HBR) patients.DES in bleedinghigh bleeding high risk bleeding risk risk in aaHBR currentcurrentina current patients withHBRa currentin DES.DES. patients withHBR DES. patients with DES. with 1-monthwith 1-monthwith DAPT. 1-month DAPT. DAPT. (HBR) patients.(HBR) patients.(HBR) patients. a currenta current DES.a current DES. DES.
ResoluteResoluteResoluteResolute OnyxOnyx Onyx DESDES Onyx DES isis notnot DES is currentlycurrentlynot is currentlynot currently indicatedindicated indicated indicated forfor HBRHBR for HBR patientsforpatients HBR patients patients onon 1-month1-month on 1-month on 1-month DAPTDAPT DAPT inin DAPT thethe in UnitedUnitedthe in Unitedthe States.States. United States. States. ResoluteResolute OnyxResolute DESOnyx is DES notOnyx currentlyis DESnot currently is not indicated currently indicated for indicatedHBR for patients HBR for patients HBR on 1-month patients on 1-month DAPTon 1-month inDAPT the UnitedDAPTin the inUnited States. the United States. States.
ONYXONYXONYX ONE ONE ONE CLEAR CLEAR CLEAR STUDY STUDY STUDY ANALYSIS ANALYSIS ANALYSIS11 1 1 COMPLEXCOMPLEXCOMPLEX ONYXONYX ONEONYX ONE CLEAR ONE CLEAR CLEAR STUDY STUDY STUDY ANALYSIS ANALYSIS ANALYSIS1 1 1 COMPLEXPATIENTPATIENTCOMPLEXPATIENTCOMPLEX pp << 0.0010.001p < 0.001p < 0.001 nn == 1,491/1,5061,491/1,506n = 1,491/1,506n = 1,491/1,506 PATIENTPOPULATIONPOPULATIONPATIENTPOPULATIONPATIENT p < 0.001p < 0.001p < 0.001 n = 1,491/1,506n = 1,491/1,506n = 1,491/1,506 POPULATIONPOPULATIONPOPULATION 9.79.79.7 PERFORMANCEPERFORMANCEPERFORMANCE mmmmmm 9.7GOALGOAL9.7** GOAL*9.7* 373737 PERFORMANCEPERFORMANCEPERFORMANCE AVERAGEAVERAGEAVERAGEmm mm GOAL* GOAL* * 3737 37 mm GOAL AVERAGESTENTEDSTENTEDAVERAGESTENTED AVERAGE LENGTHLENGTHLENGTH
1–12 months 1–12 months 1–12 months 1–12 months STENTEDSTENTEDSTENTED Event Rates (%) Rates Event (%) Rates Event (%) Rates Event (%) Rates Event 7.07.07.0 LENGTHLENGTHLENGTH 1–12 months 1–12 months 1–12 months Event Rates (%) Rates Event Event Rates (%) Rates Event Event Rates (%) Rates Event 7.07.0 7.0 4.84.84.8 %%% 2.62.62.6 4.84.84.8 3.43.43.4 0.70.70.7 3636%36% % 3.43.43.40.7 0.70.7 36PRIORPRIOR PRIOR 36 PrimaryPrimaryPrimary2.6CardiacCardiac2.6Cardiac2.6 MI MI MI TLRTLRTLR Def/Prob Def/Prob Def/Prob ST ST ST PRIORREVASCULARIZATIONREVASCULARIZATION36 REVASCULARIZATIONPRIOR EndpointEndpointEndpoint DeathDeathDeath PRIOR PrimaryPrimaryPrimaryCardiacCardiacCardiacMI MI MI TLRTLRTLR Def/Prob Def/Prob ST Def/Prob ST ST REVASCULARIZATIONREVASCULARIZATIONREVASCULARIZATION EndpointCardiacCardiacCardiacDeath Death Death/MIEndpointDeath/MIDeath/MIEndpoint Death CardiacCardiacCardiac %%% Death/MIDeath/MIDeath/MI 3939%39% % 39DIABETESDIABETES39DIABETES39 DIABETESDIABETESDIABETES VisitVisit ourVisit our website our website website to reviewto reviewto review additional additional additional clinical clinical clinical data data and data and and VisitlearnlearnVisitlearn our morelearnmore Visitourwebsite more more websiteaboutaboutour about towebsite about thethereview to the Onyx Onyxreview the to Onyx additional review OnyxONEONE additional ONE MonthONEMonth additional clinicalMonth Month clinical DAPTDAPT dataDAPT clinical DAPT Program.Program.data and Program. data andProgram. and learnlearn morelearn more about more about the about Onyxthe Onyx the ONE Onyx ONE Month ONE Month DAPT Month DAPT Program. DAPT Program. Program. medtronic.com/OnyxONEprogrammedtronic.com/OnyxONEprogrammedtronic.com/OnyxONEprogram medtronic.com/OnyxONEprogrammedtronic.com/OnyxONEprogrammedtronic.com/OnyxONEprogram HealthTrustHealthTrustHealthTrust Contract Contract Contract #3040 #3040 #3040 11 KirtaneKirtane1 Kirtane A,A, 1etet Kirtane al. al.A, One Oneet al. A, MonthMonth One et al. Month One DualDual Month Antiplatelet AntiplateletDual Antiplatelet Dual Antiplatelet TherapyTherapy Therapy inin High HighTherapy in Bleeding BleedingHigh in Bleeding High RiskRisk Bleeding Patients:Patients: Risk Patients: Risk PrimaryPrimary Patients: Primary ResultsResults Primary Results ofof OnyxOnyx Results of OnyxONEONE of Clear.OnyxClear.ONE Clear. PresentedONEPresented Clear.Presented online onlinePresented online atat ACCACC online at 2020. 2020.ACC at 2020. ACC 2020. HealthTrustHealthTrust ContractHealthTrust Contract #3040 Contract #3040 #3040 1 Kirtane A, et al. One1 Kirtane Month A, Dualet al. AntiplateletOne Month TherapyDual Antiplatelet in High Bleeding Therapy Risk in High Patients: Bleeding Primary Risk Patients:Results of Primary Onyx ONE Results Clear. of PresentedOnyx ONE onlineClear. Presentedat ACC 2020. online at ACC 2020. 1 Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020. STARTING LINE OVERVIEW
Continued from page 4
Program Components | Spend Analytics Technology / 2116 ENTITIES
PURCHASED SERVICES: OPTIMIZED FOR VALUE Valify Solutions Group’s powerful data categorization and Some of the biggest barriers to savings expert quality control measures quickly and accurately are collecting, accessing, categorizing and (38% of Total Spend) dissecting data. Now, through the Valify cleanses your health system’s entire AP spend data to platform, savings opportunities are identified immediately and members gain visibility to immediately identify competitive contracts within our spend at a category level. Through pinpoint portfolio. Members learn the full scope of their purchased benchmarking, VSG can offer details at the line-item level. services expenses and can quantify actual savings to their bottom line.
Gain total spend visibility with the Valify Solutions Group
# industry-leading Spend Analytics technology platform. Our Bicmedi 17.121.299 REACH OUT to your HealthTrust Spend Analytics platform automates spend categorization Account Manager or join@valifysolu-
into 1,200+ unique purchased services categories across /Finan... tionsgroup.com to start the Spend Vendoes purchased services conversation. seven different service lines, providing clients with detailed visibility down to the line item level. Valify Solutions Group’s Spend Analysis Dashboard. | Valify Solutions Group With proprietary benchmarking analysis, market share Custom Sourcing Events insights, and prebuilt category-specific RFP templates, ContinuedValify Solutionsfrom page 7 Group helps its members source local vendors Valify Solutions Group’s purchased services expense and services when needed in order to maximize on-contract * Performance goal derived from contemporary 1-month DAPT trials, including ZEUS, LEADERS FREE, and SENIOR trials. spend and minimize compliance issues. When the opportunity management technology provides a proven end-to-end Resolute Onyx™ Zotarolimus-eluting Coronary Stent System Precautions Potential Adverse Events Indications .Only physicians who have received adequate training should perform Other risks associated with using this device are those associated solution for organizations to proactively manage expense, arises,The Resolute our Onyx™ customZotarolimus-eluting sourcing Coronary Stent System events implantation team of the will stent. .aggregateSubsequent stent restenosis the or occlusion with percutaneous coronary diagnostic (including angiography is indicated for improving coronary luminal diameters in patients, may require repeat catheter-based treatments (including balloon and IVUS) and treatment procedures. These risks (in alphabetical including those with diabetes mellitus, with symptomatic ischemic dilatation) of the arterial segment containing the stent. The long-term order) may include but are not limited to: .Abrupt vessel closure increase staff productivity, and realize significant savings. spendheart disease and due tovolume de novo lesions of from length ≤ 35 mm multiple in native membersoutcome following repeat to catheter-baseddrive the treatments best of previously .Access site pain, hematoma, or hemorrhage .Allergic reaction (to coronary arteries with reference vessel diameters of 2.0 mm to implanted stents is not well characterized. .The risks and benefits of contrast, antiplatelet therapy, stent material, or drug and polymer 5.0 mm. In addition, the Resolute Onyx™ Zotarolimus-eluting the stent implantation should be assessed for patients with a history coating) .Aneurysm, pseudoaneurysm, or arteriovenous fistula valueCoronary for Stent participantsSystem is indicated for treating through de novo chronic totalGroup of severe RFPs. reaction to contrast agents. .Do not expose or wipe the (AVF) .Arrhythmias, including ventricular fibrillation. Balloon occlusions. product with organic solvents such as alcohol. .The use of a drug- rupture .Bleeding .Cardiac tamponade .Coronary artery occlusion, |
Access to Industry Leading Purchased Services eluting stent (DES) outside of the labeled indications, including use perforation, Supply Chain Operations rupture, or dissection .Coronary artery spasm .Death Contraindications in patients with more tortuous anatomy, may have an increased risk .Embolism (air, tissue, device, or thrombus) .Emergency surgery: The Resolute Onyx™ Zotarolimus-eluting Coronary Stent System is of adverse events, including stent thrombosis, stent embolization, peripheral vascular or coronary bypass .Failure to deliver the stent Contract Portfolio Purchasedcontraindicated for use in: Services .Patients with a known hypersensitivityAdvisory MI, Solutions or death. .Care should be taken to control the position of the .Hemorrhage requiring transfusion .Hypotension/hypertension or allergies to aspirin, heparin, bivalirudin, clopidogrel, prasugrel, guide catheter tip during stent delivery, stent deployment, and .Incomplete stent apposition .Infection or fever .MI .Pericarditis ticagrelor, ticlopidine, drugs such as zotarolimus, tacrolimus, sirolimus, balloon withdrawal. Before withdrawing the stent delivery system, .Peripheral ischemia/peripheral nerve injury .Renal failure Valify Solutions Group helps hospitals and IDNs take control Oureverolimus, experienced or similar drugs or any team other analogue can or derivative align stakeholders,confirm complete balloon implementdeflation using fluoroscopy to avoid arterial .Restenosis of the stented artery .Shock/pulmonary edema .Stable .Patients with a known hypersensitivity to the damage caused by guiding catheter movement into the vessel. .Stent or unstable angina .Stent deformation, collapse, or fracture .Stent cobalt-based alloy (cobalt, nickel, chromium, and molybdenum) or thrombosis is a low-frequency event that is frequently associated with migration or embolization .Stent misplacement .Stroke/transient of low-visibility, fragmented service categories with average centralizedplatinum-iridium alloy contracting, .Patients with a known hypersensitivity develop to the anmyocardial initiative infarction (MI) roadmap or death. Data from thefor RESOLUTE clinical ischemic attack .Thrombosis (acute, subacute, or late) ™ BioLinx polymer or its individual components trials have been prospectively evaluated and adjudicated using the Adverse Events Related to Zotarolimus definition developed by the Academic Research Consortium (ARC). savings of 10-25% on over 250 contracts in the contract identifiedCoronary artery stenting savings is contraindicated opportunities, for use in: .Patients in and manage expenses Patients’ exposure to zotarolimus is directly related to the total whom antiplatelet and/or anticoagulation therapy is contraindicated The safety and effectiveness of the Resolute Onyx™ stent have not amount of stent length implanted. The actual side effects/ .Patients who are judged to have a lesion that prevents complete yet been established in the following patient populations: .Patients complications that may be associated with the use of zotarolimus are portfolio supporting all purchased services categories goinginflation forward. of an angioplasty balloon or proper placement of the stent or with target lesions that were treated with prior brachytherapy or not fully known. The adverse events that have been associated with stent delivery system the use of brachytherapy to treat in-stent restenosis of a Resolute the intravenous injection of zotarolimus in humans include but are Warnings Onyx™ stent .Women who are pregnant or lactating .Men intending not limited to: .Anemia .Diarrhea .Dry skin .Headache .Hematuria to father children Pediatric patients Patients with coronary artery including clinical, facility, operational, and more. Valify .Please ensure that the inner package has not been opened . . .Infection .Injection site reaction .Pain (abdominal, arthralgia, or damaged as this would indicate the sterile barrier has been reference vessel diameters of < 2.0 mm or > 5.0 mm .Patients with injection site) .Rash evidence of an acute ST-elevation MI within 72 hours of intended breached. .The use of this product carries the same risks associated Please reference appropriate product Instructions for Use for more stent implantation Patients with vessel thrombus at the lesion site Solutions Group members rely on our extensive purchased withcoronary artery stent implantation procedures, which include . information regarding indications, warnings, precautions, and Patients with lesions located in a saphenous vein graft, in the left subacute and late vessel thrombosis, vascular complications, and/or . potential adverse events. bleeding events. This product should not be used in patients who are main coronary artery, ostial lesions, or bifurcation lesions .Patients . CAUTION: Federal (USA) law restricts this device to sale by or on the services contract portfolio for market competitive rates. not likely to comply with the recommended antiplatelet therapy. with diffuse disease or poor flow distal to identified lesions .Patients with three-vessel disease order of a physician. ™ The safety and effectiveness of the Resolute Onyx stent have not been established in the cerebral, carotid, or peripheral vasculature.
Medtronic LifeLine Customer Support Product Services Tel: 707.525.0111 Tel: 877.526.7890 Tel: 888.283.7868 Tel: 763.526.7890 UC202100334 EN ©2020 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. All other brands are trademarks medtronic.com of a Medtronic company. For distribution in the USA only. 10/2020
8 | Fourth Quarter 2020
To identify purchased services improvement opportunities and implement best practices, contact the VSG team today at 615.344.3000 or email [email protected]. Vital signs FDA WATCH
Product vigilance when you need it the most FDA & HealthTrust help root out faulty & fraudulent sanitizers, masks
A flood of new masks and hand sanitizers that have been manufactured to meet demand during the COVID-19 pandemic has prompted the Food and Drug Administration (FDA) to offer guidance on faulty and fraudulent versions, and HealthTrust is guiding members to be vigilant. “With manufacturing being shut down in China for two to three months and a lot of the PPE (personal protective equipment) coming out of China, supplies quickly dried up in other parts of the world,” explains Karen Wagener, BS, ChE, Executive Director, Quality & Regulatory at HealthTrust. “As we were trying to source new supplies, the biggest challenge was verifying these new sources met the appropriate level of protection.” Carey Watkins, RN, MSN, Director of Clinical iStockphoto.com/Tzido Engagement, Private Label at HealthTrust, says FDA guidance is just one piece of the puzzle. “I feel very confident and HealthTrust’s decisions also typically align with FDA relieved to have the FDA’s guidance as a starting point,” she guidance and product approvals. But the pandemic explains. “But with HealthTrust’s recommendations and compelled the FDA to accelerate product reviews, and the product review process, I feel we’ve gone several steps agency recognized many unproven medical products—some further, as well as assisting in the vetting of products for our with fraudulent claims—over the last several months. After suppliers to assure that their specifications are acceptable launching “Operation Quack Hack” in March, the FDA from a regulatory and clinical perspective. Ultimately, this identified more than 700 such products related to COVID-19 ensures products are safe for our clinicians to use.” by June. This crackdown was balanced with the FDA’s move to ADAPTING TO A CHANGING LANDSCAPE omit certain manufacturer requirements in order to expedite As part of its normal course of business, HealthTrust is product availability during PPE shortages. For example, the well-positioned to vet products that may be added to the FDA waived the need to file a 510(k) market clearance prior contract portfolio. Five Clinical Advisory Boards support to marketing surgical masks over the summer. However, strategic sourcing by applying evidence and knowledge according to Wagener, the agency later added another to this process, complementing the efforts of the internal pathway to legally market masks and clarified what should Strategic Sourcing team. be included on labels for fluid barrier protection.
Fourth Quarter 2020 | 9 “The landscape for regulatory requirements is still changing in regard to what manufacturers, importers and distributors have to do to legally market and sell hand sanitizers and face masks,” Wagener explains. “While it was necessary for the FDA to do what it did to ensure hospitals didn’t have additional shortages of PPE, it shifted the burden of legitimacy to the purchaser.” HealthTrust’s team has capably met the challenge both in comprehensively vetting products and communicating with members about what’s safe and unsafe. “Having a team dedicated to reviewing, interpreting and applying the regulations, and vetting products from a clinical perspective, is vital to ensuring only safe and effective products are available to our iStockphoto.com/andresr members,” Wagener says. “I think other organizations might not have fared as well, ending up with more counterfeit HAND SANITIZER SAFETY or adulterated products.” Angie Mitchell, RN, AVP, Clinical The Food and Drug Administration (FDA) has provided Services at HealthTrust, agrees. the following updates to ensure the safety of all “Because the measures and structure consumers when using hand sanitizer: are in place, we’re able to do a really good job of vetting,” she says. “And it does take a village.” � Do not use hand sanitizers from manufacturers on FDA’s “Do Not Use” list: fda.gov/handsanitizerlist GOING ABOVE & BEYOND � Do not use sanitizers containing methanol, or wood Beyond the critical task of verifying products, quality alcohol, as it can be toxic. control efforts from HealthTrust extended to other � Hand sanitizer must include denatured alcohol aspects, such as making sure various mask models fit to make it bitter and less appealing to ingest, clinicians. “We also had to make sure that the products particularly by children. the manufacturers were stating their testing belonged � The product is meant for external use only and is to were actually the products they shipped,” Watkins not for ingestion, inhalation or intravenous use. explains. “There was a lot of bait and switch going on.” � Labeling must discourage accidental or HealthTrust member facilities can take some intentional ingestion. reassurance from these backbone measures, say � As part of the FDA’s efforts to protect consumers, Wagener and Watkins. the agency is following up on false claims “We’re able to either help prevent a bad product from regarding hand sanitizer and has recently issued getting into the hospital or quickly act with a supplier warnings to companies for selling fraudulent to recall it,” Wagener explains. “We’ve seen enough bad COVID-19 products. apples and untruthful players that I don’t think we’ll ever � There are currently no FDA-approved products to go back to the days of solely relying on the FDA. Our prevent or treat COVID-19. efforts will supplement and complement the FDA’s final decisions for vetting these types of devices.” Watkins urges HealthTrust members to take advan- For a shareable infographic on hand sanitizer safety, tage of both the FDA’s and HealthTrust’s websites to visit education.healthtrustpg.com/clinical-resources/ hand-sanitizer-infographic keep abreast of rapidly changing information regarding safe and unsafe PPE products.
10 | Fourth Quarter 2020 Welcome to a more
INTELLIGENT solution
Designed with predictive fall monitoring technology, the CareView Patient Safety System assists with both sitter costs and patient falls.
Patient Monitoring
The SitterView® Monitoring System is an invaluable tool that increases safety and improves workfl ow, allowing one staff member to:
• Monitor up to 40 patients • Engage in 1-way or 2-way communication with patients • Document patient risks and adjust workfl ows accordingly
An Intelligent Turnkey System
The Patient Safety System incorporates diff erent camera options specifi cally designed to address your clinical needs. Leveraging CareView’s patented Virtual Rails® predictive technology, the CareView Patient Safety System uses machine learning to identify behaviors of an at-risk patient.
• Designed to improve patient safety • Helps to reduce sitter costs • Assists with staff effi ciency
Ready to learn more? Schedule your demo today.
972.943.6050 | [email protected]
CareView Fixed Controller CareView Portable Controller
care-view.com
HealthTrust Contract #12344 Vital signs Rx CONNECTION
In search of an alternative Amid escalating drug costs, safe & competitive options to imported drugs are prioritized iStockphoto.com/exipreess
If there had been any uncertainty, the COVID-19 pandemic national security risk to have active has made it clear that our country’s strong reliance on product ingredients (API) for mission- imported drugs—particularly as medication costs continue critical drugs being manufactured in to soar overall—is a precarious strategy from both a supply countries outside of the United States, chain and safety standpoint. HealthTrust is heeding this such as China,” he says. message by helping expand member access to proven alternatives at more competitive prices. A MATTER OF SAFETY & COST Most drugs sold in the United States are produced outside Several egregious examples of drug price gouging and the country, according to the World Trade Organization. quality control lapses since the turn of the new century have Experts say this fact verifies that drug integrity is just raised awareness among consumers, healthcare leaders and as vital as sourcing an array of options that save money. legislators about the importance of alternatives to imported International supply chain disruptions related to the drugs. According to Peel and Blazo, these examples include: pandemic also resulted in shortages of some medications. “If we import medications, it can increase competition � The death of more than 80 patients in 2008 from adulter- and result in better pricing for patients,” ated heparin manufactured in China, which the Food and says Haley Peel, PharmD, BCPS, Director Drug Administration (FDA) determined was intentional to of Clinical Pharmacy Member Support cut production costs. at HealthTrust. “I support competition � Daraprim, a drug long-considered the standard of care for and better pricing, but it’s important to treating a life-threatening parasitic infection, skyrocketed have visibility into the drug supply chain from $13.50 to $750 per tablet overnight in 2015, after in order to ensure quality medications a Switzerland-based company acquired the rights to reach the patients. Importing medications produce it (as reported by The New York Times). complicates the process and could increase the risk of adulterated drugs entering the supply chain. If you have At Franciscan Alliance, the prescriptions that could most no insight into what you’re consuming, the integrity of the often benefit from alternatives to imported drugs are high- supply chain is a big concern.” use generic injectables and older drugs that are off-patent, David Blazo, RPh, VP, Pharmacy Services at Franciscan but mission-critical, says Blazo. These include heparin, the Alliance in Mishawaka, Indiana, agrees: “It’s probably a antibiotic cefazolin and the heart drug isoproterenol.
12 | Fourth Quarter 2020 “Sometimes drug manufacturers bidding for multiple, large chain of medications. Among other efforts, the program GPO [group purchasing organization] contracts bid below requests detailed supply chain information from partners their own costs of manufacturing,” Blazo explains, “and when and incorporates the information as part of the contracting they win that bid, they find themselves alone in the market and evaluation, explains Peel. increase prices. It’s a situation that repeats itself over and over.” “We also look at FDA inspection history and focus on the viability and sustainability of vendors’ supply chains prior to POINTING TO SOLUTIONS contract pricing discussions,” Peel explains. “Our members Lawmakers have attempted to address drug cost and can enter into an agreement with the manufacturing partner integrity problems with various forms of recent legislation, so they can mitigate supply swings on critical products and Peel says. Notably, the Securing America’s Medicine Cabinet obtain a market-competitive price.” Act was introduced by Congress in March 2020. The bill aims This process ultimately has the patient at the center. to establish a National Centers of Excellence in Advanced “Quality is first and foremost,” Peel adds. Pharmaceutical Manufacturing to train future workers to research and implement these technologies and also spur pharmaceutical companies to bring drug manufacturing back to the United States. HealthTrust’s key effort in this realm has been creating the FOR MORE INFORMATION, visit the SIMS & Drug Shortage SIMS (Supply Interruption Mitigation Strategies) program Strategy Center on the Member Portal. to help ensure both a high-quality and reliable supply
Failure is not an option, but your choice of therapy is.
Powerful options from Getinge: from IABP to ECLS. Whether your patients are facing the early stages of heart failure or a more serious cardiac situation, you can look to Getinge for a broad range of effective, easy-to-use heart failure treatment options. Our Cardiosave IABP technology helps patients whose hearts are beginning to fail while creating a critical window of time that enables clinicians to determine the best next steps if additional treatment is necessary. In more critical cases, our Cardiohelp System combines hemodynamic stabilization with oxygenation to provide full cardiopulmonary support. Cardiosave Cardiohelp
From the smallest to greatest of cardiac needs, you’ve got complete support in the Cath Lab with Getinge.
HealthTrust Contract #4717 & 4718 www.GetingeUSA.com/CathLab
Getinge is a registered trademark of Getinge AB or its subsidiaries or affiliates in the United States or other countries. • Refer to Instructions for Use for current indications, warnings, contraindications, and precautions. • MCV00035415 REVB
The CARDIOHELP System is for circulatory and/or pulmonary support for periods up to six hours. The Source June 2020 IABP Choice Ad MCV00035415 REVA_GET_halfpg.indd 1 Fourth Quarter 2020 | 5/28/20 10:12 AM 13 Operator experience BOTTOM LINE iStockphoto.com/oatawa Making it work
Innovations in staffing during COVID-19
SINCE THE COVID-19 PANDEMIC STRUCK THIS SPRING, challenges. “There has been a significant amount of unease hospital systems have found themselves facing significant and fear due to all of the unknowns throughout the hurdles around staffing. These pitfalls range from not being pandemic,” Lopez says. able to find staff willing and able to work, to overstaffing, as patient volume fell due to canceled elective procedures. SOLVING SHORTAGES “We have seen every type of challenge imaginable,” says These obstacles have required healthcare systems to pivot Rich Lopez, Vice President of inSight Advisory Services and develop strategies to adjust to the new normal. for HealthTrust Workforce Solutions. “Many hospital system leaders are not familiar with “Organizations needed to alter their best-practice methods to redeploy or reduce the workforce standard work environments and began appropriately,” explains Lopez. Enter Workforce Solutions. managing staff from home on levels never Workforce Solutions is a HealthTrust advisory service before seen.” designed to help members solve a wide range of workforce On top of that struggle, uncertainty issues. “One key aspect of our solution is to provide around the virus itself created added Continued on page 16
14 | Fourth Quarter 2020 2002 2004 2007 2012 First ultra Ultra non-compliant, First and only Next generation, First and only non-compliant large diameter, fi ber balloon o ered large diameter, fi ber balloon fi ber balloon fiber balloon in longer lengths1,2 fi ber balloon up to 40 ATM1
The Fiber Balloons You Know and Can Trust
BD has been leading the way for almost 20 years when it comes to o ering a comprehensive portfolio of fi ber PTA balloon solutions. We take pride in continuing to o er expert service, support, and PTA balloons that you can count on to deliver care to your AV, PAD, and Venous patients when needed.
1 On the U.S. Market as of July 2020. 2 Dorado™ PTA Catheter off ered in sizes up to 200 mm. HealtTtrust Contract #7110 Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions. © 2020 BD. BD, the BD logo, Atlas, Conquest, and Dorado are trademarks of Becton, Dickinson and Company or its affi liates. All Rights Reserved. Illustrations by Mike Austin. Copyright © 2020. All Rights Reserved. Bard Peripheral Vascular, Inc. | www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281 BD-18897 Operator experience BOTTOM LINE
Continued from page 14
management of the end-to-end vendor and contingent labor � Recruiting and staffing models tailored to the member’s engagement process through our Managed Service Provider individual needs, including nursing, physicians, locum (MSP) program,” explains Lopez. tenens and interim leadership The group serves as a labor consultant, providing � Managing the end-to-end vendor and contingent labor numerous services to members, including: engagement process as a natural extension of existing supply chain management and talent acquisition teams � Advisory services and solutions focused on assessing and optimizing labor management and productivity HELPING MEMBERS THROUGH � Managed clinical services to help members address UNCERTAIN CIRCUMSTANCES specialty needs such as nursing and clinical training Throughout the pandemic, Lopez and his team—together programs and credentialing with HealthTrust’s Clinical Advisory Services—assisted � Labor management technology, including web-based members by publishing three guides: Staffing Considerations scheduling, staffing, operational benchmarking and labor During a Pandemic, Managing Work-from-Home Staff and productivity modules that provide a comprehensive view Facility Staffing Resource Pools. of key labor metrics Continued on page 18
Deadline: Dec. 16, 2020 Proposals for sessions to be ANNOUNCING considered for presentation at HTU 2020 are being accepted 2021 HTU CALL between now and Dec. 16, 2020 . FOR PROPOSALS Using Google Chrome as your browser, visit www.conferenceabstracts. com/healthtrust2021.htm to submit your program idea for review. Members and industry subject matter (No submissions will be accepted experts are invited to share impactful after Dec. 16.) clinical initiatives or supply chain success stories with HealthTrust members during the annual HealthTrust University Questions? Conference event. Email [email protected]
2021 HealthTrust University Conference | July 26 – 28 | Music City Center | Nashville | Tennessee
16 | Fourth Quarter 2020 Welcome to HALYARD. IT’S OFFICIAL: Halyard is now on the HealthTrust contract for Sterile Drapes, Packs and Gowns. That means you can start taking advantage of Halyard’s “Made in the Americas” supply reliability, innovative surgical products, insight-driven strategies - and implementation expertise to help you make the switch. Welcome to all Halyard can offer you! Learn more about us at: https://go.hyh.com/halyard-surgical/
Healthtrust Contract #46129 *Registered Trademark or Trademark of O&M Halyard or its affiliates. ©2020. All rights reserved. 008204 COPY-03631 Operator experience BOTTOM LINE
Continued from page 16 helping recruit contract staff to fill open staffing needs at The staffing considerations guide, for instance, encourages member hospitals.” member organizations to ask a series of questions to better When it comes to staffing challenges, Lopez explains, “One understand their staffing needs and challenges. These include: of our most common recommendations is for healthcare organizations to build a flexible workforce as a key strategy, � What types of patients and symptoms will be most likely so the facility can quickly respond to known seasonal to increase in number? fluctuations as well as unforeseen circumstances.” � What clinical, ancillary, support and administrative That means staffing each department or service in the personnel are needed to provide care to pandemic patients hospital with full-time, part-time and contingent labor, as and to provide support to the caregivers? appropriate. “This allows departmental and senior leadership � What clinical and administrative personnel are available? to be able to respond more quickly to ever-changing staffing needs,” Lopez adds. The guide then provides step-by-step instructions to answer those questions. “We also offer labor management assessments that define ACCESS WORKFORCE SOLUTIONS through your variable departmental staffing targets in order to offer HealthTrust Account Director or at healthtrustpg.com/ guidance on staffing levels as patient volume increases workforce. For more information, contact Rich Lopez at or decreases,” Lopez said. The services also include [email protected] recruiting. “We spent a significant amount of time
18 | Fourth Quarter 2020 Join us at RSNA 2020 to Explore the Bayer Radiology Virtual Experience!
MEDRAD® Stellant has a new FLEX Appeal.
Within the CT Suite, members can upgrade to the MEDRAD® Stellant FLEX CT Injection System and take advantage of new technology and enhanced pricing on Stellant FLEX syringes. Current Stellant Dual customers have access to seamless, low-cost upgrades through TechCARE® or FLEXChoice.
Take advantage of this special, low-cost FLEXChoice package for HealthTrust members.
A low-cost FLEXChoice upgrade Special for HealthTrust Members, select one of the including the new Workstation 3.0 following enhanced value options: 1 additional year of service warranty coverage 16 boxes of FLEXD-150-SPK syringe kits (20 kits per box)
To learn more, contact your local Bayer representative or visit StellantFLEX.com.
Bayer, the Bayer Cross, MEDRAD Stellant FLEX, MEDRAD, Stellant FLEX, MEDRAD Stellant and Stellant are trademarks HealthTrust Contract #500173 owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for information purposes. No relationship or endorsement should be inferred or implied. ©2020 Bayer. PP-M-STE-F-US-0149-1 August 2020 Consider this TECH TRENDS
The DOCTOR will see you NOW
Virtual waiting rooms are PRIOR TO THE COVID-19 PANDEMIC, JUST 11% OF crucial to keeping AMERICANS USED TELEMEDICINE. That number jumped to 46% in 2020—and experts predict it’s only going to grow telemedicine running in the coming years. smoothly Although some aspects of medicine don’t translate perfectly in a virtual model, it’s proven to be an effective way to treat patients during the pandemic. Not only can patients visit their physicians from the safety of their homes, but they can experience reduced waiting times through the use of virtual waiting rooms. With virtual waiting rooms, patients check in for an appointment using the healthcare facility’s telemedicine Continued on page 22
20 | Fourth Quarter 2020 ai158507573611_VMED_Advertisement_HeartSync-10Tabs-OnePage-AD-PRINT_032420_V3_ME.pdf 1 3/24/2020 2:49:01 PM